Comorbid ASD in youth with ADHD is linked to greater healthcare utilization and distinct medication treatment patterns.

Cannabinoid therapies may alleviate agitation in Alzheimer disease, though somnolence remains a primary safety concern.

Usual care in combination with Project Life Force lowers the risk for actual suicide attempts and improves coping skills in veterans with high risk.

School bullying correlates with depression and internet addiction, but emotional resilience serves as a protective factor for adolescents.

Social determinants of health are associated with neurobiologic abnormalities in schizophrenia-spectrum psychotic conditions.

The US Department of Health and Human Services Office of Inspector General reports on significant denial rates for post-hospital care.

Middle-aged adults with positive plasma biomarkers for Alzheimer disease show accelerated decline in specific cognitive domains.

Nonmedical use of ADHD stimulants by adults is frequently motivated by a desire to improve concentration or stay alert and is often associated with other substance use disorders.

Viloxazine extended-release shows promise for treating adults with ADHD who also experience symptoms of depression and anxiety.

Patient portals and other virtual health care options are expanding, with notable growth in patient portal messaging between 2020 and 2025.

Childhood inattentive ADHD symptoms are associated with adverse occupational outcomes and higher stress levels in adulthood.

Standardized diagnostic interviews show moderate-to-substantial test-retest reliability for adult psychiatric and substance use disorders.